&lt;p&gt;Primary Prostatic Extra-Gastrointestinal Stromal Tumor Treated with Imatinib Mesylate as Neoadjuvant and Adjuvant Therapy: A Case Report and Literature Review&lt;/p&gt;

Shen, Haixiang; Wang, Zhize; Feng, Mei; Liu, Jin; Li, Jiangfeng; Xu, Xin

doi:10.2147/ott.s233868

Cited by 6 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rarely seminoma 8,11,16,21 and a single case of adrenal neuroblastoma were reported 19 . Additional 52 articles included case reports of the association (Table 3) 2,3,5,24-55 , or a primary genitourinary organ GIST (Table 4) [56][57][58][59][60][61][62][63][64][65][66][67][68][69][70][71][72] .…”

Section: Resultsmentioning

confidence: 99%

The association of genitourinary cancer among Saudi patients with gastrointestinal stromal tumors and a systematic literature review

Seyam

Chaer

Abouelkhair

et al. 2023

Sci Rep

View full text Add to dashboard Cite

The gastrointestinal tract's most commonly occurring primary mesenchymal tumor is the gastrointestinal stromal tumor (GIST). However, few cases worldwide were reported associated with renal cell carcinoma (RCC). Therefore, we aimed to identify the association of genitourinary tumors in patients with GIST in our tertiary care hospital in Saudi Arabia and compare it to the literature. We identified all patients in the pathology department database with the diagnosis of GIST. We excluded duplicate and recurrent cases. We examined patients’ files for the presence of RCC, adrenal tumors, or other genitourinary cancer. A systematic review of the association was conducted. From 2003 to 2020, 170 patients had a histopathologic diagnosis of primary GIST, 100 men and 70 women, median age of 57 (range 9–91) years at the time of diagnosis. The site of primary GIST was gastric 103, small bowel 43, mesenteric 5, omentum/peritoneum 7, abdomen 4, isolated adrenal 1, and other 7. Six patients had associated primary genitourinary cancer. Three patients had RCC (two clear cell RCC and one radiologic diagnosis only), and three had adrenal tumors (one adrenal carcinoma, one an isolated adrenal GIST, and one pheochromocytoma). In addition, two patients had a tumor invading the urinary bladder. Although the cohort included 63 men aged 60 or above (median 71 ± 8.7 years, range 60–94), none demonstrated clinical prostatic carcinoma. Data was compared to 69 systematic review articles. We report the rare association between GIST tumors and primary genitourinary cancer, mainly RCC and adrenal tumors. Also, we identified a secondary invasion of the urinary bladder. Unlike the reported series, none of the older male patients had clinical prostate cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

The association of genitourinary cancer among Saudi patients with gastrointestinal stromal tumors and a systematic literature review

Seyam

Chaer

Abouelkhair

et al. 2023

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Considering EGISTs are not sensitive to conventional chemotherapy and radiotherapy, imatinib mesylate is proposed as adjuvant therapy for advanced, unresectable, and metastatic cases. As a tyrosine kinase inhibitor of c-kit and PDGFRA, imatinib mesylate has been proven to be an effective therapy for GISTs and EGISTs 13 . Tumor size and mitotic activity have been reported as significant prognostic factors, which should be considered for precise risk stratification and classification.…”

Section: Discussionmentioning

confidence: 99%

Primary extragastrointestinal stromal tumor of the prostate: review of the literature and case report

Benabdallah

Othmane

Ouahchi

et al. 2023

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Introduction and importance: The extragastrointestinal stromal tumor (EGIST) is defined as a mesenchymal neoplasm arising from soft tissues outside the gastrointestinal tract, and the prostate is a rare presentation site. Case presentation: A 58-year-old man was presented with lower urinary tract symptoms for 6 months. A digital rectal examination revealed a markedly enlarged prostate with a smooth, bulging surface. Prostate-specific antigen density was 0.5 ng/ml. MRI of the prostate showed an enlarged prostatic mass with hemorrhagic necrosis. Transrectal ultrasound-guided prostate biopsy was performed and pathological reports suggested a gastrointestinal stromal tumor. The patient refused radical prostatectomy and received only imatinib treatment. Clinical discussion: The diagnosis of EGIST of the prostate is extremely rare and depends on the histopathologic features with immunohistochemical results. The treatment is essentially based on radical prostatectomy, but there are other therapeutic modalities associating surgery with adjuvant or neoadjuvant chemotherapy. For patients refusing surgery, treatment with imatinib alone appears to be a therapeutic solution. Conclusion: Despite the rarity, EGIST of the prostate should be included in the differential diagnosis of patients presenting with lower urinary tract symptoms. There is no consensus regarding the treatment of EGIST, and the patients are treated as per the risk stratification.

show abstract

“…Since Van Der Aa et al. 3 reported the first case of primary prostatic EGIST in 2005, only 14 cases 3 – 16 in the English language appear in PubMed. We performed a pooled analysis of these 14 patients, plus our case ( Table 1 ).…”

Section: Discussionmentioning

confidence: 99%

“…GISTs account for approximately 4% to 7% of soft tissue sarcomas in the abdominal cavity; 2 EGIST is relatively rare. Since Van Der Aa et al 3 reported the first case of primary prostatic EGIST in 2005, only 14 cases [3][4][5][6][7][8][9][10][11][12][13][14][15][16] in the English language appear in PubMed. We performed a pooled analysis of these 14 patients, plus our case (Table 1).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Current knowledge of primary prostatic extra-gastrointestinal stromal tumor: a case report and review of the literature

Yang

et al. 2021

J Int Med Res

View full text Add to dashboard Cite

The patient was a 62-year-old man diagnosed as having prostatic extra-gastrointestinal stromal tumor (EGIST) who was treated with imatinib. No recurrence or metastasis was found after a 6-month follow-up. We identified 14 cases of prostatic primary EGIST in PubMed and summarized these cases with our case. The patients’ ages ranged from 31 to 78 years (average: 53.6 years), and most patients’ prostate-specific antigen (PSA) concentrations were within normal limits (92.9%, 13/14). All patients underwent imaging examinations; prostatic masses measured 6 to 14.2 cm (mean: 9.43 cm), and imaging excluded secondary prostatic masses from the intestinal tract. By immunohistochemical staining, the tumors were positive for cluster of differentiation (CD)117 (71.4%, 10/14), DOG1 (100%, 7/7), and CD34 (100%, 14/14), and negative for smooth muscle actin (SMA) (71.4%, 10/14), desmin (100%, 11/11), and S100 (100%, 12/12). Treatment depended on the results of the gene mutation detection as well as the risk estimation according to tumor size and microscopic mitotic rates (>5 per 50 high-power fields: 60%, 6/10). Among the 12 patients with reported outcomes, nine achieved good results (no recurrence or metastasis), one achieved reduced mass volume, one experienced recurrence, and one died.

show abstract

<p>Primary Prostatic Extra-Gastrointestinal Stromal Tumor Treated with Imatinib Mesylate as Neoadjuvant and Adjuvant Therapy: A Case Report and Literature Review</p>

Cited by 6 publications

References 22 publications

The association of genitourinary cancer among Saudi patients with gastrointestinal stromal tumors and a systematic literature review

The association of genitourinary cancer among Saudi patients with gastrointestinal stromal tumors and a systematic literature review

Primary extragastrointestinal stromal tumor of the prostate: review of the literature and case report

Current knowledge of primary prostatic extra-gastrointestinal stromal tumor: a case report and review of the literature

Contact Info

Product

Resources

About